Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma

MLA

Nicholas D. Klemen, et al. “Patterns of Failure after Immunotherapy with Checkpoint Inhibitors Predict Durable Progression-Free Survival after Local Therapy for Metastatic Melanoma.” Journal for ImmunoTherapy of Cancer, vol. 7, no. 1, July 2019, pp. 1–9. EBSCOhost, https://doi.org/10.1186/s40425-019-0672-3.

APA

Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, Daniel J. Boffa, Sajid A. Khan, Kelly Olino, James Clune, Stephan Ariyan, Ronald R. Salem, Sarah A. Weiss, Harriet M. Kluger, Mario Sznol, & Charles Cha. (2019). Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal for ImmunoTherapy of Cancer, 7(1), 1–9. https://doi.org/10.1186/s40425-019-0672-3

Chicago

Nicholas D. Klemen, Melinda Wang, Paul L. Feingold, Kirsten Cooper, Sabrina N. Pavri, Dale Han, Frank C. Detterbeck, et al. 2019. “Patterns of Failure after Immunotherapy with Checkpoint Inhibitors Predict Durable Progression-Free Survival after Local Therapy for Metastatic Melanoma.” Journal for ImmunoTherapy of Cancer 7 (1): 1–9. doi:10.1186/s40425-019-0672-3.